Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Shrinking team NBB
FTE fell two years in a row, from 22.4 to 19.3.
-
Figures corrected NBB
Corrected annual account filed for 2025.
Financials
Financial year 2025
INTRESSA VASCULAR from Gembloux, company number BE0462587258, closed financial year 2025 with a result of € -2 million after tax. For that financial year INTRESSA VASCULAR recorded revenue of € 0 and equity of € 11.8 million. Compared with financial year 2024, the result moved from € -2.6 million to € -2 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 8, 2026.
€ 11.8 million
▼ 8% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2 million
▲ 21 % less loss than in 2024
Profit after tax over the fiscal year.
€ 2.3 million
▼ 63% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -10.5 million.
People and assets in 2025
19.3
▼ 0.6 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.8 million
▼ 3% vs 2024
€ 91,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 24,662
▼ 48% vs 2024
Of which on lease € 3,449.
Debts at end 2025
€ 6,001
▼ 73% vs 2024
Loans from banks and other lenders, long and short.
€ 773,884
▲ 12% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 476,681
▲ 26% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 329,209 | - | € 33,024 | € 0 | ▼ 100% |
| Gross margin | € -432,685 | € 200,407 | € -172,494 | € 624,567 | ▲ € 797,061 |
| Profit after taxes | € -3,187,557 | € -3,238,000 | € -2,561,733 | € -2,013,922 | ▲ € 547,811 |
| Equity | € 4,457,936 | € 13,840,689 | € 12,864,147 | € 11,773,918 | ▼ 8% |
| Total debts | € 5,180,007 | € 5,290,437 | € 2,362,039 | € 2,565,743 | ▲ 9% |
| Cash | € 5,286,092 | € 11,398,347 | € 6,323,996 | € 2,319,987 | ▼ 63% |
| Land & buildings | - | - | - | € 6,161 | |
| Retained profit | € -2,663,121 | € -5,901,121 | € -8,462,854 | € -10,476,776 | ▼ € 2 million |
| Bank debt | € 1,231,307 | € 531,924 | € 22,615 | € 6,001 | ▼ 73% |
| Balance sheet total | € 9,637,943 | € 19,131,126 | € 15,226,186 | € 14,339,662 | ▼ 6% |
| Employees (FTE) | 24.3 | 22.4 | 19.9 | 19.3 | ▼ 0.6 |
Key figures of INTRESSA VASCULAR, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to INTRESSA VASCULAR?
What happened at INTRESSA VASCULAR in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Chong Wang stepped down as director. NBB
- Bellerive & Co Management stepped down as director. NBB
- ODMC BV stepped down as director. NBB
- Noshaq Partners SCRL stepped down as director. NBB
- Pierre Douette stepped down as director. NBB
- Pierre Lefebvre stepped down as director. NBB
- DG International Consulting SRL stepped down as director. NBB
- Corrected annual accounts filed for financial year 2025. Source: NBB ↗
In short
From € 3.2 million loss in 2022 to € 2 million loss in 2025.
On average € 32,400 of value added per employee in 2025.
Management
The stake of Wallonie Entreprendre, LEMANOS, J.P. III comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
INTRESSA VASCULARThe shares are held by Wallonie Entreprendre (6.9%), LEMANOS (0.1%) and J.P. III (0.1%). It owns 25% of Shanghai Kaiyitong Medical Technology CO., LTD itself.
Directors
According to the 2025 annual accounts
Chairman of the board · represented by Philippe Felten
Also active at: SCHREDER, Capaul, CISEO, CILYX GROUP, CILYX
since 2024 · until 2027
Director · represented by Olivier DELPORTE
Also active at: Miracor Medical, ENDO TOOLS THERAPEUTICS, Samantree Medical
since 2021 · until 2027
Chong Wang
Director
since 2022 · until 2028
Director · represented by Eric BRANDT
Also active at: CAUTION MUTUELLE DES METIERS ET NEGOCES, Fonderies J. Marichal Ketin et Cie, DARDENNE, SOGECOM, VITAVERDE.BIO, HAEMERS Technologies, SPACEBEL, NOSHAQ VENTURE +169 more
since 2021 · until 2027
DG International Consulting SRL
Director · represented by Denis GESTIN
Also active at: SYNERGIA MEDICAL, ENDO TOOLS THERAPEUTICS
since 2023 · until 2026
since 2021 · until 2027
Pierre Lefebvre
Director
since 2021 · until 2027
Shareholders
Participations
Shanghai Kaiyitong Medical Technology CO., LTD
25%
Establishments
Establishment units
Physical locations of this company
Rue Jules Poskin,Isnes 3
5032 Gembloux
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0462.587.258
- VAT number
- BE 0462.587.258
- Registered office
- Rue Jules Poskin,Isnes 3, 5032 Gembloux
- Names & denominations
- INTRESSA VASCULAR · CARDIATIS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 4 February 1998
- Peppol
- Active · Active since 21 Oct 2026
- Activities · NACE
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied